Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2016-07-28 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis presentation at Bioshares 2016 Biotech Summit 22 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed business overview and strategic presentation of Pharmaxis, focusing on drug development, partnerships, product portfolio, and business development strategy. It includes forward-looking statements, descriptions of drug discovery programs, competitive landscape, and partnership deals. There are no financial statements, quarterly or annual results, audit opinions, or regulatory certifications. The content is typical of an investor presentation aimed at providing detailed information on the company's strategy, pipeline, and market opportunities to investors and stakeholders. The length and depth of the document support this classification. Therefore, the document is best classified as an Investor Presentation (IP).
2016-07-28 English
Appendix 3B - issue of employee options and shares 13 pages 138.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including ordinary shares and performance rights, their terms, issue prices, purpose, and application for quotation on the ASX (Australian Securities Exchange). It references specific ASX rules and sections related to securities issuance and quotation. The content is focused on announcing and providing details about a new share issue and related securities, not a financial report or earnings release. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes.
2016-07-25 English
Proposed Issue of Securities to Chief Executive Officer 2 pages 115.4KB
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange announcing a proposed issue of securities (performance rights) to the Chief Executive Officer. It references compliance with Listing Rule 3.10.3 and states that shareholder approval will be sought at the upcoming Annual General Meeting. The document also mentions that further details will be included in the 2016 Statutory Annual Report. The content is an announcement of a capital issuance related to employee incentives, not the actual issuance or detailed financial data. The document length is short (2523 characters) and primarily serves as a notification rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2016-07-25 English
Pharmaxis Completes Recruitment of CF Clinical Trial for US 2 pages 150.5KB
Capital/Financing Update Classification · 90% confidence The document is a media release dated 15 July 2016 from Pharmaxis Ltd announcing the completion of recruitment for a clinical trial (CF303) for Bronchitol in cystic fibrosis patients targeting the US market. It discusses the trial design, partnership with Chiesi, funding, and expected timelines for FDA approval. The content is focused on a clinical trial update and strategic partnership rather than financial results, regulatory filings, or management changes. It is not an earnings release, annual or interim report, or any form of regulatory filing. The document is a corporate announcement about a clinical trial milestone and partnership funding, which fits best under Capital/Financing Update (CAP) because it includes information about funding commitments (US$22 million from Chiesi, total trial cost US$26 million, and milestone payments). It is not a report publication announcement or a regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-07-14 English
BIO 2016 - Shareholder Update 2 pages 286.8KB
Investor Presentation Classification · 90% confidence The document is a shareholder update letter dated 21 June 2016 from the CEO of Pharmaxis. It discusses recent investor meetings, participation in the BIO 2016 International Convention, and updates on various drug development programs and market interest. The letter mentions that a Quarterly Report and full year financial results will be provided in July, indicating this is a communication prior to the release of formal financial reports. The content is narrative and strategic in nature, aimed at shareholders to provide business progress and outlook rather than detailed financial statements or regulatory filings. It is not a formal Annual Report, Interim Report, Earnings Release, or any regulatory filing. The document is a shareholder update letter, which fits best under Investor Presentation (IP) as it provides detailed information for investors about company strategy, market positioning, and business developments.
2016-06-20 English
Investor presentation 9 June 2016 24 pages 1.2MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed corporate presentation or report from Pharmaxis, covering business overview, drug development pipeline, partnerships, management team, product portfolio, clinical trial data, and financial statistics. It includes extensive narrative on company strategy, drug discovery, collaborations, and financial figures for fiscal years ending June 2014, June 2015, and nine months ended March 2016. The length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or summary. There is no indication that this is a transcript of a call, a proxy statement, or a regulatory filing. The content aligns with a comprehensive periodic financial and business report shorter than a full fiscal year, consistent with an Interim / Quarterly Report (IR). 9M 2016
2016-06-08 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.